Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Niagen Bioscience, Inc. (NAGE)

Healthcare Biotechnology
3.40 $
+2.4% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Niagen Bioscience, Inc. (NAGE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.8% of the shares are freely tradable; institutional investors hold 47.2%.

Ownership Structure

Institutional ownership
47.2%
Insiders
29.3%
Float
74.8%
Short % of float
8.7%
Shares Outstanding
80Mio.

Largest Shareholders

Institutions

Institutions NAGE
Name Stake (%) Shares Change (%) Date
BlackRock Inc 4.86 3,871,619 -5.0 03/31/2026
Steel Peak Wealth Management LLC 4.24 3,373,000 +0.0 03/31/2026
Vanguard Group Inc 4.13 3,286,498 -18.3 12/31/2025
Arrowstreet Capital Limited Partnership 2.99 2,378,437 +47.1 03/31/2026
Vanguard Capital Management, LLC 2.70 2,149,277 +0.0 03/31/2026
Tieton Capital Management, LLC 2.55 2,029,155 +23.3 03/31/2026
Qube Research & Technologies 2.15 1,714,639 +61.5 03/31/2026
UBS Group AG 1.76 1,405,531 -0.4 03/31/2026

Funds

Funds NAGE
Name Stake (%) Shares Change (%) Date
Tieton Small Cap Value 2.55 2,029,155 +23.3 03/31/2026
Vanguard Total Stock Mkt Idx Inv 1.85 1,470,818 +0.0 04/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
30. Jun 2026 Lopez Carlos Luis SVP, General Counsel Other 2,314 2.71 6,271
30. Jun 2026 Pamir Ozan Chief Financial Officer Other 4,255 2.71 11,531
30. Jun 2026 Fried Robert N Chief Executive Officer Other 1,106 2.71 2,997

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?